We're thrilled to share the exciting news from our member PannTheraPi! Their Phase 1 clinical trial for PTI5803 has yielded positive results, paving the way for further development of this groundbreaking treatment for resistant epilepsy. Congratulations to the entire team! #epilepsy #deeptech #biotech
PannTheraPi is delighted to announce positive results for its Phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of our PTI5803 drug product. This study was performed with the support of our investors and European Commission via the EIC Accelerator program, thank you. Congratulations to the whole team for this main achievement for the company allowing to pursue the development of our first in class product in a resistant epilepsy, demonstrating the interested of our target and validating our platform for the next generation of products under development. #epilepsy #deeptech #biotech